LEL Lilly(Eli)

 
TIDMLEL 
 
Issue Date: May 14, 2012 
 
Media Alert 
 
Media Contacts: 
 
Amy Sousa (Lilly) Office: (317) 276-8478 Mobile: (317) 997-1481 
 
Neil Hochman (TogoRun) Office: (212) 453-2067 Mobile: (516) 784-9089 
 
         LILLY ONCOLOGY TO HIGHLIGHT FINAL RESULTS FOR PHASE III STUDY 
 
                      IN MOST COMMON FORM OF LUNG CANCER 
 
PARAMOUNT Study One of More than 25 Lilly Oncology Studies at Key Cancer Meeting 
 
INDIANAPOLIS, May 14, 2012 - Eli Lilly and Company (NYSE: LLY) will present 
data from more than 25 studies at the 48th Annual Meeting of the American 
Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 - 5, 2012, 
including overall survival results from PARAMOUNT, a Phase III study of an 
ALIMTA® (pemetrexed for injection)-based continuation maintenance regimen for 
the treatment of advanced nonsquamous non-small cell lung cancer. Lilly 
presented progression-free survival data from PARAMOUNT at the 2011 ASCO 
meeting. 
 
Other Lilly Oncology research being presented at ASCO will include additional 
clinical data on ALIMTA. 
 
ALIMTA Studies: 
 
  * Abstract # LBA7507: Oral Abstract Session: Monday, June 4, 2012; 5:15 PM - 
    5:30 PM 
 
  * 
      + PARAMOUNT: Final overall survival results of the phase III study of 
        maintenance pemetrexed plus best supportive care versus placebo plus 
        BSC immediately following induction treatment with pem plus cisplatin 
        for advanced nonsquamous non-small cell lung cancer 
 
      + Author/Speaker: Luis Paz-Ares 
 
      + Location: E Hall D2 
 
  * Abstract # 7002: Oral Abstract Session: Monday, June 4, 2012; 8:30 AM - 8: 
    45 AM 
 
  * 
      + Phase II Study of pemetrexed plus carboplatin or cisplatin with 
        concurrent radiation therapy followed by pemetrexed consolidation in 
        patients with favorable-prognosis inoperable stage IIA/B non-small cell 
        lung cancer 
 
      + Author/Speaker: Hak Choy 
 
      + Location: E Hall D2 
 
P-LLY 
 
                                     # # # 
 
This press release contains forward-looking statements about the potential of 
ALIMTAand reflects Lilly's current beliefs. However, as with any pharmaceutical 
product, there are substantial risks and uncertainties in the process of 
development and commercialization. There is no guarantee that the product will 
continue to becommercially successful. For further discussion of these and 
other risks and uncertainties, see Lilly's filings with the United States 
Securities and Exchange Commission. Lilly undertakes no duty to update 
forward-looking statements. 
 
 
 
Eli Lilly and Company 
 
Lilly Corporate Center 
 
Indianapolis, Indiana 46285 
 
U.S.A. 
 
 
 
 
 
                                     - 2 - 
 
 
 
 
END 
 

Lilly(Eli) (LSE:LEL)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

Lilly(Eli) (LSE:LEL)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025